If you're starting medication-assisted treatment (MAT) for opioid use disorder, or if you're already on buprenorphine, methadone, or naltrexone, you've probably asked the question: how long do patients stay on MAT?
It's the single most common question clinicians hear, and unfortunately, it's also the one most answered vaguely or inconsistently. Some providers say "a few months." Others say "as long as you need it." And some programs impose arbitrary limits like 30 or 90 days that have nothing to do with your clinical needs.
Here's the truth: the research on MAT duration is actually quite clear. And you deserve to know what it says.
This article breaks down what the evidence tells us about optimal treatment timelines for buprenorphine, methadone, and naltrexone. We'll look at why most relapses happen within 90 days of stopping, what clinical factors actually predict successful tapering, and how to have the right conversation with your provider about when (and whether) to discontinue.
Why There's No Universal Answer to MAT Duration
The honest answer to "how long should I stay on MAT?" is: it depends. But not in a vague, hand-wavy way. It depends on specific, measurable clinical factors that research has identified as predictors of success or relapse.
These include the severity of your opioid use disorder, how long you used opioids before treatment, whether you have co-occurring mental health conditions like depression or anxiety, your social supports and living situation, and your prior treatment history. Someone with a five-year fentanyl habit, unstable housing, and three previous overdoses has different clinical needs than someone with a one-year prescription opioid problem and strong family support.
The medication matters too. Buprenorphine (Suboxone), methadone, and naltrexone (Vivitrol) work differently in the body and brain, and the research on optimal duration varies by medication.
What's consistent across all three: the evidence strongly favors longer treatment over shorter treatment. And the biggest risk factor for relapse isn't staying on MAT too long. It's stopping too soon.
What the Research Says About Buprenorphine Duration
Buprenorphine (often prescribed as Suboxone, which combines buprenorphine with naloxone) is the most commonly prescribed MAT medication. So how long should you take it?
The data is clear: longer is better. Studies consistently show that staying on buprenorphine for at least 12 months produces dramatically better outcomes than short-term treatment of 30 to 90 days.
Research published in Pediatrics found that only about 24% of patients maintain high adherence for 12 months, but those who do have significantly lower rates of emergency department use and hospitalization compared to those who discontinue in under three months. The study authors recommend clinicians counsel patients to plan for at least 12 months of treatment.
Even more sobering: a mortality study found that shorter buprenorphine treatment durations are associated with incrementally higher risk of death after discontinuation. Patients who stopped after 8 to 30 days had a 1.25 times higher mortality risk, those who stopped after 31 to 90 days had 1.59 times higher risk, and those stopping after 91 to 180 days had 1.93 times higher risk, all compared to longer treatment durations like 181 to 365 days.
Research from Massachusetts General Hospital found that while average buprenorphine episodes last only 8 to 9 months (with half lasting less than 4 months), treatment lasting at least 15 months was associated with the greatest improvements and reductions in adverse events. For optimal outcomes, the researchers suggest retention of 1.9 to 2 years may be needed.
Unfortunately, the trend is going in the wrong direction. A JAMA Network Open study found that median buprenorphine treatment duration has actually decreased over time, dropping from 51 days in 2014-2016 to just 38 days in 2020-2022.
Translation: most people are stopping buprenorphine way too soon, and it's costing lives.
How Long to Take Suboxone for Opioid Addiction: The Clinical Reality
So if the research says 12 to 24 months minimum, why do so many people stop sooner?
Often, it's because of stigma. Patients worry they're "trading one addiction for another" or feel pressure from family members who don't understand how MAT works. Some treatment programs still promote the outdated idea that "real recovery" means being completely medication-free.
But here's what the science actually says: buprenorphine is not getting you high if it's prescribed correctly. It's normalizing brain chemistry that was disrupted by chronic opioid use. It's allowing your brain's reward system to recalibrate while you build the life skills, social supports, and coping mechanisms that sustain long-term recovery.
Think of it like insulin for diabetes or antidepressants for major depression. You wouldn't stop insulin after three months because you're "feeling better." You stay on it because it's treating an underlying condition.
For many patients, the right answer to "how long should I take Suboxone?" is: as long as it's helping you stay alive and build a life worth living. For some, that's 18 months. For others, it's five years. And for some, it's indefinite maintenance, and that's clinically appropriate.
The Methadone Timeline: What Long-Term Maintenance Really Means
Methadone is typically dispensed daily at opioid treatment programs (OTPs) and has been the gold standard for severe opioid use disorder for over 50 years. It's especially effective for people with long histories of opioid use, prior treatment failures, or polysubstance use.
Methadone treatment timelines tend to be longer than buprenorphine, often measured in years rather than months. Research consistently shows that patients who stay on methadone for at least two years have significantly better outcomes than those who taper earlier.
"Indefinite maintenance" doesn't mean you're stuck forever. It means you and your treatment team are prioritizing stability and quality of life over an arbitrary timeline. Many people successfully taper off methadone after several years of stable recovery, but the taper is slow (often taking 6 to 12 months) and medically supervised.
Successful discharge from an OTP typically involves years of demonstrated stability: consistent negative drug screens, stable housing and employment, strong social supports, effective coping skills, and absence of cravings. Even then, many clinicians recommend transitioning to buprenorphine rather than stopping all MAT, because the relapse risk after complete discontinuation remains high.
The data on early methadone discontinuation is stark: most patients who leave treatment in the first 90 days return to opioid use within weeks. The protective effect of methadone disappears as soon as you stop taking it.
Naltrexone Duration: A Different Timeline for a Different Mechanism
Naltrexone (often given as monthly Vivitrol injections) works differently than buprenorphine or methadone. It's an opioid antagonist that blocks the effects of opioids rather than activating opioid receptors.
Because of this mechanism, naltrexone is most effective for people who have already completed detox and have high motivation to stay abstinent. It's often used as a bridge strategy: helping people get through the first 6 to 12 months of recovery while they build other supports.
The research on optimal naltrexone duration is less robust than for buprenorphine or methadone, but most studies suggest at least 6 months of monthly injections, with many patients benefiting from 12 months or longer. The key predictor of success is whether the patient is truly ready for an antagonist-based approach (meaning they're not still experiencing significant cravings or ambivalence about stopping opioid use).
Naltrexone doesn't carry the same stigma as buprenorphine or methadone because it's not an opioid. But that doesn't make it superior. For many patients, especially those with severe OUD, buprenorphine or methadone produces better retention and outcomes.
The Early Discontinuation Problem: What Happens When You Stop Too Soon
Here's what the research tells us about stopping MAT prematurely: the first 90 days after discontinuation are the highest-risk period for relapse and overdose.
Physiologically, your brain hasn't fully healed yet. The neuroadaptations caused by chronic opioid use, changes in dopamine signaling, stress response systems, and reward processing, take months to years to normalize. When you stop MAT before that healing is complete, you're at high risk for overwhelming cravings, anhedonia (inability to feel pleasure), and return to use.
Statistically, the numbers are grim. Studies show that 40% to 60% of patients who discontinue buprenorphine in the first few months return to opioid use within 90 days. And because tolerance drops quickly after stopping, the risk of fatal overdose is dramatically higher if relapse occurs.
The most common driver of premature tapering isn't clinical improvement. It's stigma. Patients feel ashamed of being on MAT long-term. Family members pressure them to "get off everything." Employers or probation officers misunderstand MAT as continued drug use.
This is where education matters. MAT isn't prolonging addiction. It's treating a chronic medical condition. And stopping too soon isn't a sign of strength. It's a risk factor for death.
How to Have the Tapering Conversation With Your Provider
If you're thinking about tapering off MAT, that's a conversation worth having with your prescriber. But it should be a medically informed conversation, not one driven by shame or external pressure.
Here are the right questions to ask:
- What clinical milestones indicate I might be ready to consider tapering?
- How long have I been stable (no cravings, no use, strong supports, stable mental health)?
- What does a medically supervised taper timeline look like for my situation?
- What are my personal risk factors for relapse if I taper now versus waiting longer?
- What's the plan if I start experiencing cravings or return to use during or after the taper?
A good provider won't shame you for wanting to taper, but they also won't rubber-stamp a plan that puts you at high risk. They should be able to point to specific clinical indicators (not just time elapsed) that suggest you're ready.
Those indicators typically include: at least 12 to 24 months of continuous stability, resolution of co-occurring mental health symptoms, strong social supports, stable housing and employment, effective coping skills for stress and triggers, and absence of cravings. If you're not there yet, that's not failure. That's information.
A medically supervised taper should be gradual (often taking 3 to 6 months or longer), with frequent check-ins and a clear plan to resume MAT if needed. It's not a one-way door.
The Anti-MAT Bias Problem: Arbitrary Limits That Harm Patients
Unfortunately, not all treatment programs follow evidence-based practices around MAT duration. Some still impose arbitrary limits like 30-day or 90-day maximums that have no clinical justification.
These limits aren't based on research. They're based on outdated abstinence-only philosophies that view MAT as a temporary crutch rather than a legitimate long-term treatment. And they're actively harming patients.
If you're in a program that's pressuring you to taper off MAT on a predetermined timeline that doesn't match your clinical needs, that's a red flag. Evidence-based addiction treatment programs individualize MAT duration based on patient needs, not program philosophy.
You have the right to ask: What does the research say about optimal treatment duration for my situation? Why is this program's timeline different from what the studies recommend? What outcomes data does this program have for patients who taper at 30 or 90 days?
Programs that are confident in their clinical model will welcome those questions. Programs that deflect or fall back on ideology should raise concerns.
What Treatment Programs Need to Know About MAT Duration
For treatment center operators and clinicians designing MAT-integrated programs, understanding realistic treatment timelines isn't just about clinical outcomes. It affects program design, utilization review, billing, and payer credentialing strategies.
If your program is built around 30-day or 90-day episodes, but the research says optimal outcomes require 12 to 24 months of MAT, you have a structural mismatch that will hurt both patients and your program's long-term success metrics.
Building MAT programs that support long-term care requires the right infrastructure: EMR systems designed for OTPs and Suboxone clinics, workflows that support ongoing medication management and counseling, billing systems that can handle extended episodes of care, and patient engagement tools that keep people connected over months and years, not just weeks.
It also requires staff education. If your counselors or case managers are communicating (even subtly) that long-term MAT is a sign of failure, you're undermining your own clinical model.
Frequently Asked Questions About MAT Duration
Is it OK to stay on Suboxone for years?
Yes. Research shows that long-term buprenorphine maintenance (multiple years) is both safe and effective for many patients with opioid use disorder. There's no arbitrary time limit after which Suboxone stops being appropriate. Like any medication for a chronic condition, the right duration is however long it continues to provide clinical benefit and prevent relapse.
Will I have to take methadone forever?
Not necessarily. Many people successfully taper off methadone after several years of stable recovery. But "indefinite maintenance" is a clinically valid option if it's keeping you alive and helping you build a meaningful life. The decision to taper should be based on clinical stability and readiness, not shame or external pressure.
What happens if I stop MAT and relapse?
You can restart. MAT isn't a one-time opportunity. If you taper off and find yourself struggling with cravings or return to use, reaching back out to restart medication is the right move. Your tolerance will have dropped, so if you do use, start with much smaller amounts than before to avoid overdose. But the best approach is to restart MAT before relapse occurs.
How do I know if I'm ready to stop taking buprenorphine?
Clinical indicators of readiness typically include: at least 12 to 24 months of stability on MAT, resolution of co-occurring mental health symptoms, strong social supports, stable housing and employment, effective coping skills, and absence of cravings. If you're not sure, that's a conversation to have with your prescriber, not a decision to make based on what others think you "should" do.
Does insurance cover long-term MAT?
Most insurance plans, including Medicaid and Medicare, cover MAT without arbitrary time limits. However, some plans may require periodic utilization reviews to document ongoing medical necessity. If you're having coverage issues, your provider can submit documentation showing that continued MAT is medically appropriate based on your clinical needs and the research on optimal treatment duration.
Can I taper off MAT on my own?
No. Tapering should always be done under medical supervision. A provider can create a gradual taper schedule, monitor for withdrawal symptoms and cravings, adjust the pace based on your response, and have a plan to resume MAT if needed. Self-tapering significantly increases the risk of uncomfortable withdrawal and return to opioid use.
Building MAT Programs That Support Evidence-Based Care
If you're a treatment provider or program operator looking to build or expand MAT services, the research on optimal treatment duration has real implications for how you design your program.
You need clinical infrastructure that supports long-term patient relationships, not just acute episodes. You need billing and compliance systems that can handle extended MAT episodes while meeting payer requirements. You need staff who understand the evidence and can communicate it clearly to patients and families.
ForwardCare helps addiction treatment providers build MAT-integrated programs grounded in evidence-based practices. From licensing and credentialing support to EMR implementation and compliance infrastructure, we provide the operational backbone that lets you focus on patient care.
Whether you're opening a new treatment facility, adding MAT to an existing program, or optimizing your current services, we can help you build systems that support patients for as long as they need care, not just as long as your current infrastructure allows.
Learn more about how ForwardCare supports evidence-based MAT programs at forwardcare.com.
The Bottom Line on MAT Duration
How long do patients stay on MAT? The evidence says: longer than most people currently do, and longer than many programs currently support.
For buprenorphine, at least 12 to 24 months is associated with the best outcomes, with many patients benefiting from even longer treatment. For methadone, multiple years of maintenance is common and appropriate. For naltrexone, at least 6 to 12 months provides the most benefit.
The biggest risk isn't staying on MAT too long. It's stopping too soon, driven by stigma rather than clinical readiness.
If you're on MAT and wondering about your timeline, have an honest conversation with your provider about what the research says for your specific situation. If you're a treatment provider, make sure your program design and messaging align with the evidence, not outdated ideology.
MAT saves lives. And it works best when patients stay on it long enough for it to do its job.
